HK Stock Market Move | HUTCHMED (00013) rose over 5% in the afternoon. The application for the approval of the new drug Savolitinib was accepted by the National Medical Products Administration and granted priority review.

HUTCHMED (00013) rose more than 5% in the afternoon, up 4.59% to HK$28.5 as of the time of publication, with a turnover of HK$44.86 million. On the news front, HUTCHMED announced that the new drug application for tazemetostat for the treatment of relapsed or refractory follicular lymphoma in adult patients has been accepted and given priority review by the China National Medical Products Administration (NMPA). Tazemetostat is a global first-in-class EZH2 methyltransferase inhibitor developed by Epizyme, Inc., a subsidiary of AbbVie, which has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of specific relapsed/refractory follicular lymphoma patients and specific advanced epithelial sarcoma patients. It has also been approved for the treatment of specific relapsed/refractory follicular lymphoma patients by the Ministry of Health, Labour and Welfare in Japan. HUTCHMED has entered into a strategic partnership to conduct research, development, production, and commercialization of tazemetostat in mainland China, Hong Kong, Macau, and Taiwan.